Pune’s Serum Institute of India, the world’s largest vaccine maker by volume, is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222 with CEO Adar Poonawalla stating he would start manufacturing at personal risk.
In an e-mail interaction with Sohini Das, Poonawalla says the company is investing $200 million in the vaccine facility and that he wants to keep the price at below Rs 1,000. Edited excerpts: According to the results of the first two phases of trials published in The Lancet, the Oxford-AstraZeneca vaccine candidate is safe and inducing an immune ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.